Publications by authors named "C R Lewanski"
Article Synopsis
- The study focused on the long-term effects of afatinib in patients with EGFR mutant non-small cell lung cancer (NSCLC) who also had other health issues, and assessed the usefulness of monitoring circulating tumor DNA (ctDNA).
- Conducted in the UK, the TIMELY trial involved patients receiving afatinib daily until their disease progressed or they experienced significant side effects, with blood samples analyzed every 12 weeks.
- Results showed that while the median progression-free survival was 7.9 months, some patients experienced long-term benefits, and ctDNA testing improved the detection of EGFR mutations and was linked to better outcomes.
: The spatio-molecular distribution of choline and its metabolites in tumors is highly heterogeneous. Due to regulation of choline metabolism by hypoxic transcriptional signaling and other survival factors, we envisage that detection of such heterogeneity in patient tumors could provide the basis for advanced localized therapy. However, non-invasive methods to assess this phenomenon in patients are limited.
View Article and Find Full Text PDFEvaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line -paclitaxel ± durvalumab. Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. QoL was generally stable through eight treatment cycles (both arms).
View Article and Find Full Text PDFImportance: Gut dysbiosis impairs response to immune checkpoint inhibitors (ICIs) and can be caused by broad-spectrum antibiotic (ATB) therapy.
Objective: To evaluate whether there is an association between ATB therapy administered concurrently (cATB) or prior (pATB) to ICI therapy and overall survival (OS) and treatment response to ICI therapy in patients with cancer treated with ICIs in routine clinical practice.
Design, Setting, And Participants: This prospective, multicenter, cohort study conducted at 2 tertiary academic referral centers recruited 196 patients with cancer who received ICI therapy between January 1, 2015, and April 1, 2018, in routine clinical practice rather than clinical trials.
Purpose: We previously demonstrated that the median survival of patients with poor prognosis non-small cell lung cancer (NSCLC) considered unfit for first-line platinum chemotherapy was <4 months. We evaluated whether VeriStrat could be used as a prognostic or predictive biomarker in this population.
Experimental Design: We conducted a randomised double-blind trial among patients with untreated advanced NSCLC considered unfit for platinum chemotherapy because of poor performance status (PS) or multiple comorbidities.